Thread by @cperruna

1 / $TDOC

Revenue of $454M grew 151% y/y

Adjusted EBITDA of $56.6M grew 430% y/y

FY-21 Revenue guidance range raised to $1,970M to $2,020M, up from $1,950M to $2,000M

2Q-21 Revenue guidance range $495M to $505M

FY-21 Adj. EBITDA guidance range maintained at $255M to $275M

2 / Continued progress on integration of Teladoc and Livongo, including enabling Teladoc physician referrals into chronic care programs.

% of chronic care members enrolled in more than one program has grown more than 3x year-over year to >15% (was less than 5% last year).

3 / Cash, Cash Equivalents, & ST Investments
(as of March 31, 2021): $723M

Convertible & LT Debt on Balance Sheet
(as of March 31, 2021): $1.35B

Operating Cash Flow (1Q-21): $(18M)

Capital Expenditures + Capitalized Software
Development Costs (1Q-21): $13M

4 / “Consumers are embracing our whole-person virtual care offerings, engaging with multiple products
& coming to us for more of their health needs.

As our integration accelerates, we are leading the
way in whole-person care, unlocking the full spectrum of healthcare in one...

5 / ...unified and personalized consumer experience.”

Finds continued favorable consumer trends, particularly among Millennials, who are showing a greater sustained propensity to use digital health than other generations.

6 / Network of clinicians provided 3.2 million visits in 1st quarter, +50% growth over the prior year's quarter despite a weak flu season.

Significant strength in noninfectious disease & specialty visits with mental health volumes driving growth in both B2B & DTC channels.

7 / My thoughts:

If & that's a big "if", they can execute the full integration & roll-out of the Livongo services, $TDOC will remain the leader (direct & enterprise) & distance themselves as the go-to whole person care & 24/7 health monitoring option.

Staying long $TDOC shares.